Back to top
more

Amphastar Pharmaceuticals (AMPH)

(Delayed Data from NSDQ)

$42.02 USD

42.02
342,556

+0.91 (2.21%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $42.06 +0.04 (0.10%) 6:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vaishali Doshi headshot

4 Top-Performing Liquid Stock Picks for Robust Returns

by Vaishali Doshi

Here are four top-ranked liquid stocks, Puma Biotechnology (PBYI), Amphastar Pharmaceuticals (AMPH), DropBox (DBX), and Vimeo (VMEO), which investors can add to their portfolio for solid gains.

Amphastar (AMPH) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Amphastar (AMPH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Here's Why Investors Should Retain Molina Healthcare (MOH) Now

by Zacks Equity Research

Molina Healthcare (MOH) is well-poised for improvement on the back of membership growth in the Medicaid and Medicare businesses. Acquisitions and a solid cash balance act as added tailwinds.

Here's Why You Should Invest in Centene (CNC) Stock Now

by Zacks Equity Research

Robust growth outlook, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.

3 Reasons Why Growth Investors Shouldn't Overlook Amphastar (AMPH)

by Zacks Equity Research

Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.

Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?

by Zacks Equity Research

Here is how Cencora (COR) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Wall Street Analysts See Amphastar (AMPH) as a Buy: Should You Invest?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Amphastar (AMPH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Amphastar Pharmaceuticals (AMPH) Rises Yet Lags Behind Market: Some Facts Worth Knowing

by Zacks Equity Research

In the most recent trading session, Amphastar Pharmaceuticals (AMPH) closed at $45.27, indicating a +0.2% shift from the previous trading day.

Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies

by Zacks Equity Research

Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies are part of the Zacks Industry Outlook article.

Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why

by Zacks Equity Research

The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $45.19, representing a +1.23% change from its previous close.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

by Sundeep Ganoria

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.

Amphastar Pharmaceuticals (AMPH) Rises As Market Takes a Dip: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $44.72, denoting a +0.52% change from the preceding trading day.

Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why

by Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) closed at $46.47 in the latest trading session, marking a +1.55% move from the prior day.

Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.

Amphastar Pharmaceuticals (AMPH) Rises Higher Than Market: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $47.55, denoting a +0.76% change from the preceding trading day.

Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $45.74, moving -0.54% from the previous trading session.

Amphastar Pharmaceuticals (AMPH) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amphastar Pharmaceuticals (AMPH) closed at $45.88, marking a +0.81% move from the previous day.

Amphastar Pharmaceuticals (AMPH) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $46.04, moving -0.41% from the previous trading session.

Should You Invest in Amphastar (AMPH) Based on Bullish Wall Street Views?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Amphastar (AMPH) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $46.30, moving -0.73% from the previous trading session.

Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why

by Zacks Equity Research

Amphastar Pharma (AMPH) shares are up 89.1% year to date due to the acquisition of Baqsimi from Lilly. The company also receives FDA approval for Naloxone.

Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why

by Zacks Equity Research

Sales of Lilly's (LLY) new drug, Mounjaro are already benefiting from strong demand trends. Lilly expects regulatory decisions for some key pipeline candidates this year, which are key to growth.

HCA Healthcare (HCA) Rises 24% in a Year: More Room to Run?

by Zacks Equity Research

HCA Healthcare (HCA) is well-poised for growth on the back of improved patient occupancy levels, effective telehealth services suite and solid cash-generating abilities.

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: Celsius, Adobe, Curtiss-Wright in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical

by Zacks Equity Research

Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical are part of the Zacks Industry Outlook article.